• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感染后肠易激综合征

Post-infectious irritable bowel syndrome.

作者信息

Thabane Marroon, Marshall John K

机构信息

Division of Gastroenterology, McMaster University Medical Centre, Hamilton, Ontario, Canada.

出版信息

World J Gastroenterol. 2009 Aug 7;15(29):3591-6. doi: 10.3748/wjg.15.3591.

DOI:10.3748/wjg.15.3591
PMID:19653335
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2721231/
Abstract

Post-infectious irritable bowel syndrome (PI-IBS) is a common disorder wherein symptoms of IBS begin after an episode of acute gastroenteritis. Published studies have reported incidence of PI-IBS to range between 5% and 32%. The mechanisms underlying the development of PI-IBS are not fully understood, but are believed to include persistent sub-clinical inflammation, changes in intestinal permeability and alteration of gut flora. Individual studies have suggested that risk factors for PI-IBS include patients' demographics, psychological disorders and the severity of enteric illness. However, PI-IBS remains a diagnosis of exclusion with no specific disease markers and, to date, no definitive therapy exists. The prognosis of PI-IBS appears favorable with spontaneous and gradual resolution of symptoms in most patients.

摘要

感染后肠易激综合征(PI-IBS)是一种常见疾病,其肠易激综合征症状在急性肠胃炎发作后出现。已发表的研究报告称,PI-IBS的发病率在5%至32%之间。PI-IBS发生发展的潜在机制尚未完全明确,但据信包括持续性亚临床炎症、肠道通透性改变和肠道菌群变化。个别研究表明,PI-IBS的危险因素包括患者的人口统计学特征、心理障碍和肠道疾病的严重程度。然而,PI-IBS仍然是一种排除性诊断,没有特定的疾病标志物,并且迄今为止,尚无确切的治疗方法。大多数患者的症状会自发且逐渐缓解,PI-IBS的预后似乎良好。

相似文献

1
Post-infectious irritable bowel syndrome.感染后肠易激综合征
World J Gastroenterol. 2009 Aug 7;15(29):3591-6. doi: 10.3748/wjg.15.3591.
2
[Post-infectious irritable bowel syndrome].[感染后肠易激综合征]
Tunis Med. 2012 Mar;90(3):205-13.
3
Relationship between infectious gastroenteritis and irritable bowel syndrome.感染性肠胃炎与肠易激综合征之间的关系。
Clin J Gastroenterol. 2014 Feb;7(1):14-8. doi: 10.1007/s12328-013-0444-4. Epub 2013 Dec 15.
4
Almost all irritable bowel syndromes are post-infectious and respond to probiotics: controversial issues.几乎所有的肠易激综合征都是感染后引发的,且对益生菌有反应:存在争议的问题。
Dig Dis. 2007;25(3):245-8. doi: 10.1159/000103894.
5
Postinfectious irritable bowel syndrome.感染后肠易激综合征
J Pediatr Gastroenterol Nutr. 2009 Apr;48 Suppl 2:S95-7. doi: 10.1097/MPG.0b013e3181a15e2e.
6
Post-infectious irritable bowel syndrome following water contamination.水源污染后感染后肠易激综合征
Kidney Int Suppl. 2009 Feb(112):S42-3. doi: 10.1038/ki.2008.618.
7
Post-infectious irritable bowel syndrome--a review of the literature.感染后肠易激综合征——文献综述
Z Gastroenterol. 2011 Aug;49(8):997-1003. doi: 10.1055/s-0031-1281581. Epub 2011 Aug 2.
8
Almost all irritable bowel syndromes are post-infectious and respond to probiotics: consensus issues.几乎所有肠易激综合征都是感染后引发的,且对益生菌有反应:共识问题。
Dig Dis. 2007;25(3):241-4. doi: 10.1159/000103893.
9
Rome Foundation Working Team Report on Post-Infection Irritable Bowel Syndrome.罗马基金会感染后肠易激综合征工作组报告。
Gastroenterology. 2019 Jan;156(1):46-58.e7. doi: 10.1053/j.gastro.2018.07.011. Epub 2018 Nov 28.
10
Post-infectious irritable bowel syndrome.感染后肠易激综合征
Curr Gastroenterol Rep. 2006 Aug;8(4):327-32. doi: 10.1007/s11894-006-0054-0.

引用本文的文献

1
The gut virome in association with the bacteriome in gastrointestinal diseases and beyond: roles, mechanisms, and clinical applications.胃肠道疾病及其他情况下与细菌群落相关的肠道病毒组:作用、机制及临床应用
Precis Clin Med. 2025 May 28;8(2):pbaf010. doi: 10.1093/pcmedi/pbaf010. eCollection 2025 Jun.
2
Pediatric Gastrointestinal Tract Outcomes During the Postacute Phase of COVID-19.新冠病毒病(COVID-19)急性后期的儿科胃肠道结局
JAMA Netw Open. 2025 Feb 3;8(2):e2458366. doi: 10.1001/jamanetworkopen.2024.58366.
3
Crohn's disease, irritable bowel syndrome, and chronic fatigue: the importance of communication and symptom management-a case report.克罗恩病、肠易激综合征与慢性疲劳:沟通及症状管理的重要性——一例病例报告
J Med Case Rep. 2025 Jan 9;19(1):9. doi: 10.1186/s13256-024-05010-3.
4
Examination of Methods to Estimate Productivity Losses in an Economic Evaluation: Using Foodborne Illness as a Case Study.经济评估中估计生产力损失方法的考察:以食源性疾病为例
Pharmacoeconomics. 2025 Apr;43(4):453-467. doi: 10.1007/s40273-024-01458-9. Epub 2025 Jan 4.
5
Incidence and Clinical Course of Post-infectious Irritable Bowel Syndrome in Patients Admitted to University Hospitals: 1-year Prospective Follow-up Study.大学医院收治患者感染后肠易激综合征的发病率及临床病程:1年前瞻性随访研究
J Neurogastroenterol Motil. 2025 Jan 31;31(1):110-118. doi: 10.5056/jnm24018. Epub 2024 Dec 18.
6
Long-term gastrointestinal and hepatobiliary outcomes of COVID-19: A multinational population-based cohort study from South Korea, Japan, and the UK.长期胃肠道和肝胆道结局的 COVID-19:来自韩国、日本和英国的一项基于多国人群的队列研究。
Clin Mol Hepatol. 2024 Oct;30(4):943-958. doi: 10.3350/cmh.2024.0203. Epub 2024 Aug 29.
7
Low dose rifaximin combined with N-acetylcysteine is superior to rifaximin alone in a rat model of IBS-D: a randomized trial.低剂量利福昔明联合 N-乙酰半胱氨酸治疗 IBS-D 大鼠模型优于利福昔明单药治疗:一项随机试验。
Sci Rep. 2024 Aug 5;14(1):18140. doi: 10.1038/s41598-024-69162-4.
8
The gut microbiome in disorders of gut-brain interaction.肠-脑相互作用障碍中的肠道微生物组。
Gut Microbes. 2024 Jan-Dec;16(1):2360233. doi: 10.1080/19490976.2024.2360233. Epub 2024 Jul 1.
9
Pediatric Gastrointestinal Outcomes During the Post-Acute Phase of COVID-19: Findings from RECOVER Initiative from 29 Hospitals in the US.新冠病毒病(COVID-19)急性期后儿童胃肠道结局:美国29家医院的“恢复计划”研究结果
medRxiv. 2024 Jul 9:2024.05.21.24307699. doi: 10.1101/2024.05.21.24307699.
10
Environmental enrichment reverses stress-induced changes in the brain-gut axis to ameliorate chronic visceral and somatic hypersensitivity.环境富集可逆转应激诱导的脑-肠轴变化,以改善慢性内脏和躯体超敏反应。
Neurobiol Stress. 2023 Nov 24;28:100590. doi: 10.1016/j.ynstr.2023.100590. eCollection 2024 Jan.

本文引用的文献

1
The clinical course of postinfectious irritable bowel syndrome: a five-year follow-up study.感染后肠易激综合征的临床病程:一项五年随访研究。
J Clin Gastroenterol. 2009 Jul;43(6):534-40. doi: 10.1097/MCG.0b013e31818c87d7.
2
The use of probiotics in the prevention and treatment of antibiotic-associated diarrhea with special interest in Clostridium difficile-associated diarrhea.益生菌在预防和治疗抗生素相关性腹泻中的应用,尤其关注艰难梭菌相关性腹泻。
Nutr Clin Pract. 2009 Feb-Mar;24(1):33-40. doi: 10.1177/0884533608329297.
3
Probiotics and irritable bowel syndrome: rationale, mechanisms, and efficacy.益生菌与肠易激综合征:理论依据、作用机制及疗效
J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S123-5. doi: 10.1097/MCG.0b013e3181574393.
4
Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.替加色罗用于患有混合型排便习惯或便秘的肠易激综合征女性患者:一项随机对照试验。
Am J Gastroenterol. 2008 May;103(5):1217-25. doi: 10.1111/j.1572-0241.2008.01808.x.
5
Effect of Lactobacillus casei as a probiotic on modulation of giardiasis.干酪乳杆菌作为益生菌对贾第虫病调节作用的影响。
Dig Dis Sci. 2008 Oct;53(10):2671-9. doi: 10.1007/s10620-007-0197-3. Epub 2008 Feb 28.
6
Low risk of irritable bowel syndrome after Clostridium difficile infection.艰难梭菌感染后肠易激综合征风险较低。
Can J Gastroenterol. 2007 Nov;21(11):727-31. doi: 10.1155/2007/262478.
7
Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.替加色罗对以便秘为主型肠易激综合征男性患者结肠转运时间的影响。
J Gastroenterol Hepatol. 2007 Aug;22(8):1183-9. doi: 10.1111/j.1440-1746.2006.04543.x.
8
Systematic review and meta-analysis: The incidence and prognosis of post-infectious irritable bowel syndrome.系统评价与荟萃分析:感染后肠易激综合征的发病率及预后
Aliment Pharmacol Ther. 2007 Aug 15;26(4):535-44. doi: 10.1111/j.1365-2036.2007.03399.x.
9
Development of functional diarrhea, constipation, irritable bowel syndrome, and dyspepsia during and after traveling outside the USA.在美国境外旅行期间及之后出现功能性腹泻、便秘、肠易激综合征和消化不良。
Dig Dis Sci. 2008 Jan;53(1):271-6. doi: 10.1007/s10620-007-9853-x. Epub 2007 Jun 5.
10
Safety, tolerability and satisfaction with tegaserod therapy in Asia-Pacific patients with irritable bowel syndrome with constipation.替加色罗治疗亚太地区便秘型肠易激综合征患者的安全性、耐受性及满意度
J Gastroenterol Hepatol. 2007 Aug;22(8):1190-8. doi: 10.1111/j.1440-1746.2007.04955.x. Epub 2007 May 24.